Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales Analysis by Application & Disease Type The global metabolomics market will witness a robust CAGR of 13.4%, valued at $2.15 billion in 2021, expected to appreciate and reach $6.68 billion by 2030, confirms Strategic Market Research. Metabolomics is a study of biochemical processes containing intermediates and by-products of metabolic activities known as metabolomes. It includes the utilisation of various metabolomics analysis methods to determine metabolites, such as spectroscopy, multivariant analysis, and chromatography. Metabolites are related to the phenotype of an organism. They can be utilised for a vast range of applications, including phenotyping of genetically modified plants, substantial equivalence testing, identification of gene function and biotic-abiotic stress reaction analysis. It also facilitates researchers and scientists to calculate physiological effects in terms of observing the adverse reaction of drugs on an organism. As per the article “Metabolomics in the Diagnosis and Prognosis of COVID-19,” article published in July 2021, research on the application of metabolomics in the diagnosis of infectious diseases is accelerated, particularly in respiratory viral infection. Innovations in cell metabolomics and the increasing prevalence of cancer and chronic diseases are the critical factors for the market's growth, with North America dominating the overall market. Market Drivers - Increase in the Government and Private Investments in the Metabolomics Industry for the Research and Development. With the increase in life-threatening diseases like cancer and CVD, metabolomics offers an increasing focus on innovative approaches with tremendous potential leading to a rise in government and private investments in the metabolomics market. As per the WHO, Cancer is the second leading cause of death, accounting for one in six deaths. Lung, stomach, prostate, and liver cancer are the common types of cancer in men, while breast, colorectal, cervical, and thyroid cancer is the most common among women. As to The Metabolomics Innovation Centre (TMIC), metabolomics has experienced tremendous growth in the last decade with remarkable discoveries in several diseases, which have increased investments in metabolomics facilities across the globe and accelerated the appearance of more than 80 university-based metabolomics facilities across North America over the past decade. The growing global base of the geriatric population is increasing the rates of diseases such as diabetes, along with the prevalence of cancer which is thoroughly augmenting the market growth. As per the endocrine society article published in January 2022, 33 percent of adults aged 65 or older have diabetes and are at risk of developing diabetes-related complications like kidney failure, heart disease, and hypoglycemia in comparison to the younger people living with diabetes. The rapid technological advancements of the various analytical tools are also a significant driver for market growth. For instance, in June 2021, As per the official news of Bruker, it launched several products to improve the accuracy of 4D-metabolomics and lipidomics workflows, which includes a new ion source for its trapped ion mobility spectrometry time-of-flight Pro 2 platform. Restraints - High Complex Metabolomics Datasets The metabolomics techniques generate a large volume of heterogeneous data, which is complex and challenging to evaluate. Because of the chemical diversity of small molecule metabolites, it is not possible to study the data using a single analytical technique. All these factors are obstructing the prosperity of the overall market. Opportunities – Developments in the Biomarker Market and Emerging Countries Metabolomics is utilized to produce in-vitro diagnostic tools, environmental toxicology screening procedures, drug discovery and development approaches by using bioinformatics tools to uncover new metabolomics biomarkers. In medical science, biomarkers are needed to characterize better and diagnose diseases, predict adverse medication events, and identify patient groups that benefit from specific treatments. Furthermore, discovering biomarkers linked to drug safety, sensitivity, and resistance using machine learning techniques will soon create significant growth prospects for the market. The conducive market environment in the emerging countries results in the emergence of ample opportunities. The economies like India are witnessing mergers and acquisitions and collaborations between different government bodies in terms of R&D activities about metabolomics with an increase in investments from both private and public organizations, which has positively resulted in the metabolomics market growth in India. Due to the presence of High performance liquid chromatography, Secondary ion mass spectrometry and metabolomics cro along with their respective technological advancements, the market is expected to foster ample opportunities for market growth in the future. Market Analysis Of Different Segments Covered in the Report Based on Product and Service Metabolomics Instruments Separation Tools Gas Chromatography Capillary Electrophoresis Ultra-performance Liquid Chromatography High-performance Liquid Chromatography Detection Tools Nuclear Magnetic Resonance (NMR) Spectroscopy Surface-Based Mass Analysis Mass Spectrometry Bioinformatics Tools and Services Bioinformatics Services Bioinformatics Tools and Databases Based on Application Biomarker discovery Toxicology testing Personalized Medicine Metabolomics Drug discovery Nutrigenomics Functional Genomics Other Applications Based on Indication Cancer Neurological Disorders Cardiovascular Diseases Inborn Errors of Metabolism Metabolic Disorders Based on End-User Contract Research Organizations Academic and Research Institutes Pharmaceutical and Biotechnology Companies Other End-users Regional Coverage Analysis North America US Canada Europe Germany UK France Italy Spain Rest of Europe Asia Pacific Japan China India Rest of Asia Pacific Latin America Brazil Mexico The Middle East and Africa Segments Analysis & Insights Based on Product and Service, the metabolomics instruments segment dominates the overall market with a share of almost 60 percent in 2020, which is due to the rapid adoption of metabolomics and smooth technological operations that further leads to workflow efficiency, precision, reliability, and processing data. Based on Application, the biomarker discovery segment dominated the overall market with a steady CAGR in 2020 due to increased adoption of metabolic biomarkers and technological advancements. Also, among all chronic diseases, the increasing cases of cancers globally are a significant driver for drug discovery and biomarkers. As per the American Cancer Society, Global Cancer Facts statistics estimated that by 2040, the overall number of cases is expected to grow upto 27.5 million new cancer cases and 16.3 million cancer deaths. As the number of cases are rising, more and more people are going for rapid oncology tests, the demand for new drug discovery is growing at a rapid pace. Based on Indication, the cancer segment dominated the overall market share with a steady CAGR and also possesses the highest growth rate in the entire industry. As per GLOBOCAN 2020, the number of new cancer cases was estimated to be 19,292,789 in 2020, with nearly 9,958,133 deaths in 185 countries worldwide. This is due to the rise in cancer cases and the growing demand for treatment therapy for cancer. Based on End User, the academic and research institutes dominated the overall market in 2020. It is due to the increasing research activities in metabolomics and the addition of funds to the educational and research institutes for the study. Based on Region, North America held the most dominated regional share in the market in 2020 due to the existence of significant market players operating in the industry, growing research and developments, and rising preclinical activities by pharma companies. As of January 2022, the Centre for Disease Control and Prevention (CDC) shows that 4 in 10 adults have more than one or two chronic diseases, while 6 in 10 adults have a chronic disease in the United States. The significant number of cases of chronic diseases demand new and advanced treatments which can increase the applications of metabolomics and propel industry growth. Metabolomics Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 2.15 Billion The revenue forecast in 2030 USD 6.68 Billion Growth rate CAGR of approximately 13.4% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product and Service , By Application, By Indication By End User, and By Region. By Product and Service Metabolomics Instruments and Bioinformatics Tools and Services By Application Biomarker discovery, Toxicology testing, Personalized Medicine, Metabolomics Drug discovery, Nutrigenomics, Functional Genomics By Indication Cancer, Neurological Disorders, Cardiovascular Diseases, Inborn Errors of Metabolism and Metabolic Disorders By End-User Hospitals, Ambulatory Surgical Centers, Others By Region North America, Europe, Asia Pacific, LAMEA. Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Spacelabs Healthcare Inc, Bosch & Sohn GmbH & Co. KG, SunTech Medical, Schiller AG, Welch Allyn Inc, DAIFUKU CO. LTD, GE Company, Rudolf Riester GmbH, BPL Group, Mortara Instrument Inc., Vaso Corporation, Daray Medical, Microlife Corporation, Omron Healthcare Company. Global Metabolomics Market Competitive Landscape Analysis The competitive landscape analysis provides information about the crucial competitors prevailing in the global environment. The industry including metabolomics companies, is moderately competitive, focusing on educational institutes for research to develop new drugs against infectious and chronic diseases. Waters Corporation Merck KGaA GE Healthcare Hitachi High-Technologies Corporation Human Metabolome Technologies, Inc. LECO Corporation (US), Metabolon, Inc. Bio-Rad Laboratories Agilent Technologies Shimadzu Corporation Thermo Fisher Scientific Danaher Corporation Bruker Corporation PerkinElmer Scion Instruments DANI Instruments S.p.A. GL Sciences SRI Instruments Kore Technology Ltd. JASCO, Inc. Recent Developments In July 2021, Thermo Fisher Scientific along with the University of California launched a research collaboration, to provide innovations, standard operating procedures, and best practices to the metabolomics community. These initiatives are sure to provide robust market growth opportunities in the future. In June 2021, Thermo Fischer Scientific launched the Next-Generation of MS-Based Solutions Orbitrap IQ-X Tribrid mass spectrometer, which was specially designed to reveal complex chemical structures for compound identification. It also involves the process of structure elucidation of small molecules combining industry-leading mass analyzer technology with intelligent automation, real-time decision making, intuitive software, etc. In April 2021, BioMerieux received CE Marking for the VITEK MS PRIME, a novel MALDI-TOF mass spectrometry identification system, which is a crucial step in the microbiology workflow. On September, 2020, Waters Corporation announced the establishment of Immerse Cambridge, a research laboratory in the heart of Cambridge’s Kendall Square, where Waters partnered with academia to accelerate the next generation of scientific advancements In January 2020, Agilent and Thermo Fisher extended their collaboration to enhance the compatibility of Thermo Fisher’s analytical systems with Agilent’s OpenLAb Chromatography Data System, which allows users to streamline quality control workflows through improved compatibility and high-performance liquid chromatography instrumentation. Various Leading Metabolomics Devices that Key Market Leaders Develop Name of the product Function Key Players Orbitrap IQ-X Tribrid Mass Spectrometer It addresses the complexities of small-molecule identification and characterization to confidently collect meaningful data. Thermo Fisher Scientific Ion mobility spectrometry (IMS) Used for the separation of component detection and identification, including a 360 degree access to a measurable physiochemical characteristic in the form of collision cross section (CCS).. Waters Corporation, Scion instruments, Bruker Corporation Mass spectrometry It enable detection and quantification of thousands of metabolites features simultaneously. PerkinElmer, Bruker corporation, Thermo fisher Frequently Asked Question About This Report What is the metabolomics targeted and untargeted approach? Metabolomics methodologies fall into two distinct categories- Untargeted metabolomics - an intended comprehensive analysis of all the measurable analytes in a sample, including chemical unknowns, which include Exometabolomics Targeted metabolomics- a measurement of defined groups of chemically characterized and biochemically annotated metabolites uses metabolomics mass spectrometry. What are key metabolomics market trends? Increase in the government and Private investments in the metabolomics market for the research and development. What are advantages of metabolomics? • Provides the closest link to the organisms phenotype • Metabolism is highly conserved across biology • The analytical approaches are transferable across different biological systems What is the Global metabolomics platform? The Metabolomics Platform designs and implements comprehensive mass spectrometry-based analytical methods for small molecules in complicated biological samples. For various sample types, including mammalian cells, bacteria, and yeast, while offering a wide range of cutting-edge metabolomic methods. What is the difference between Metabonomics, metabolomics, and Fluxomics? Metabolomics is the study of the metabolome. Metabolomics studies a living organisms multiparametric metabolic reactions to pathogenic stimuli or genetic change. Fluxomics is a research field that assesses the rates of all intracellular fluxes in biological systems core metabolism. It combines data from various -omics domains to create a comprehensive picture of molecular interactions. How big will the Metabolomics Market be? The Global Metabolomics Market share was USD 2.15 billion in 2021 with a CAGR of 13.4 percent is predicted to reach USD 6.68 billion by 2030. The Metabolomics Market forecast period is from 2021 and 2030. Sources 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Digital Therapeutics Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Market 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Analysis 4.3.1 By region, 2021 - 2030 (USD Million) 4.4 By Sales Channel Analysis 4.4.1 By Sales Channel, 2021 - 2030 (USD Million) 4.5 By Product Type Analysis 4.5.1 By Product Type, 2021 - 2030 (USD Million) 4.6 Application Analysis 4.6.1 By Application, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 PEST analysis 4.9.2 Porter’s analysis 4.10Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Digital Therapeutics Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Application Analysis 5.11.1. Trends in Application (2014-2020) 5.11.2. Trends in Application (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Digital Therapeutics Manufacturing Sites, Area Served, Product Sales Channel 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Sales Channel Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021 - 2030) 7.3. B2C 7.3.1. B2C Market, 2021 - 2030 (USD Million) 8.3.1.1 Patients Market, 2021 - 2030 (USD Million) 8.3.1.2 Caregivers Market, 2021 - 2030 (USD Million) 7.4. B2B 7.4.1. B2B Market, 2021 - 2030 (USD Million) 7.4.1.1 Providers Market, 2021 - 2030 (USD Million) 7.4.1.2 Payers Market, 2021 - 2030 (USD Million) 7.4.1.3 Employers Market, 2021 - 2030 (USD Million) 7.4.1.4 Pharmaceutical Companies Market, 2021 - 2030 (USD Million) 7.4.1.5 Other Buyers Market, 2021 - 2030 (USD Million) 8. Global Market: By Product Type Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021 - 2030) 8.3. Software 8.3.1. Software Market, 2021 - 2030 (USD Million) 8.4. Device 8.4.1. Device Market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021 - 2030) 9.3. Preventive Applications 9.3.1. Preventive Applications Market, 2021 - 2030 (USD Million) 9.3.1.1 Obesity Market, 2021 - 2030 (USD Million) 9.3.1.2 Nutrition Market, 2021 - 2030 (USD Million) 9.3.1.3 Lifestyle Management Market, 2021 - 2030 (USD Million) 9.3.1.4 Prediabetes Market, 2021 - 2030 (USD Million) 9.3.1.5 Other Preventive Applications Market, 2021 - 2030 (USD Million) 9.4. Treatment/Care-related Applications 9.4.1. Treatment/Care-related Applications Market, 2021 - 2030 (USD Million) 9.4.1.1 Diabetes Market, 2021 - 2030 (USD Million) 9.4.1.2 CNS Disorders Market, 2021 - 2030 (USD Million) 9.4.1.2.1 Mental Health Disorder Market, 2021 - 2030 (USD Million) 9.4.1.2.2 Other CNS Digital therapeutics Market, 2021 - 2030 (USD Million) 9.4.2. Chronic Respiratory Disorders Market, 2021 - 2030 (USD Million) 9.4.3. Musculoskeletal Disorders Market, 2021 - 2030 (USD Million) 9.4.4. Cardiovascular Diseases Market, 2021 - 2030 (USD Million) 9.4.5. Smoking Cessation Market, 2021 - 2030 (USD Million) 9.4.6. Medication Adherence Market, 2021 - 2030 (USD Million) 9.4.7. Gastrointestinal Disorders Market, 2021 - 2030 (USD Million) 9.4.8. Substance Use & Addiction Management Market, 2021 - 2030 (USD Million) 9.4.9. Rehabilitation & Patient Care Market, 2021 - 2030 (USD Million) 9.4.10. Other Treatment/Care-related Applications Market, 2021 - 2030 (USD Million) 10. Global Market: Regional Outlook 10.1 North America 10.1.1. North America, By Sales Channel, 2021 - 2030 (USD Million) 10.1.2. North America, By Product Type, 2021 - 2030 (USD Million) 10.1.3. North America, By Application, 2021 - 2030 (USD Million) 10.1.4. North America, By Country, 2021 - 2030 (USD Million) 10.1.4.1. U.S. 10.1.4.1.1. U.S., By Sales Channel, 2021 - 2030 (USD Million) 10.1.4.1.2. U.S., By Product Type, 2021 - 2030 (USD Million) 10.1.4.1.3. U.S., By Application, 2021 - 2030 (USD Million) 10.1.4.2.Canada 10.1.4.2.1. Canada, By Sales Channel, 2021 - 2030 (USD Million) 10.1.4.2.2. Canada, By Product Type, 2021 - 2030 (USD Million) 10.1.4.2.3. Canada, By Application, 2021 - 2030 (USD Million) 10.2. Europe 10.2.1. Europe , By Sales Channel, 2021 - 2030 (USD Million) 10.2.2. Europe Market, By Product Type, 2021 - 2030 (USD Million) 10.2.3. Europe Market, By Application, 2021 - 2030 (USD Million) 10.2.4. Europe Market, By country, 2021 - 2030 (USD Million) 10.2.4.1 U.K. 10.2.4.1.1. U.K. , By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.1.2. U.K. , By Product Type, 2021 - 2030 (USD Million) 10.2.4.1.3. U.K. , By Application, 2021 - 2030 (USD Million) 10.2.4.2. Germany 10.2.4.2.1. Germany, By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.2.2. Germany , By Product Type, 2021 - 2030 (USD Million) 10.2.4.2.3. Germany , By Application, 2021 - 2030 (USD Million) 10.2.4.3. France 10.2.4.3.1. France , By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.3.2. France , By Product Type, 2021 - 2030 (USD Million) 10.2.4.3.3. France , By Application, 2021 - 2030 (USD Million) 10.2.4.4. Rest of Europe 10.2.4.4.1. Rest of Europe, By Sales Channel, 2021 - 2030 (USD Million) 10.2.4.4.2. Rest of Europe, By Product Type, 2021 - 2030 (USD Million) 10.2.4.4.3. Rest of Europe, By Application, 2021 - 2030 (USD Million) 10.3. Asia Pacific 10.3.1. Asia Pacific By Sales Channel, 2021 - 2030 (USD Million) 10.3.2. Asia Pacific , By Product Type, 2021 - 2030 (USD Million) 10.3.3. Asia Pacific , By Application, 2021 - 2030 (USD Million) 10.3.4. Asia Pacific By country, 2021 - 2030 (USD Million) 10.3.4.1. China 10.3.4.1.1. China By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.1.2. China By Product Type, 2021 - 2030 (USD Million) 10.3.4.1.3. China By Application, 2021 - 2030 (USD Million) 10.3.4.2. India 10.3.4.2.1. India By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.2.2. India By Product Type, 2021 - 2030 (USD Million) 10.3.4.2.3. India By Application, 2021 - 2030 (USD Million) 10.3.4.3. Japan 10.3.4.3.1. Japan By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.3.2. Japan By Product Type, 2021 - 2030 (USD Million) 10.3.4.3.3. Japan By Application, 2021 - 2030 (USD Million) 10.3.4.4. South Korea 10.3.4.4.1. South Korea By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.4.2. South Korea By Product Type, 2021 - 2030 (USD Million) 10.3.4.4.3. South Korea By Application, 2021 - 2030 (USD Million) 10.3.4.5. Rest of ASIA PACIFIC 10.3.4.5.1. Rest of ASIA PACIFIC By Sales Channel, 2021 - 2030 (USD Million) 10.3.4.5.2. Rest of ASIA PACIFIC By Product Type, 2021 - 2030 (USD Million) 10.3.4.5.3. Rest of ASIA PACIFIC By Application, 2021 - 2030 (USD Million) 10.4. Latin America 10.4.1. Latin America By Sales Channel, 2021 - 2030 (USD Million) 10.4.2. Latin America By Product Type, 2021 - 2030 (USD Million) 10.4.3. Latin America By Application, 2021 - 2030 (USD Million) 10.4.4. Latin America By country, 2021 - 2030 (USD Million) 10.4.4.1. Brazil 10.4.4.1.1. Brazil By Sales Channel, 2021 - 2030 (USD Million) 10.4.4.1.2. Brazil By Product Type, 2021 - 2030 (USD Million) 10.4.4.1.3. Brazil By Application, 2021 - 2030 (USD Million) 10.4.4.2. Mexico 10.4.4.2.1. Mexico By Sales Channel, 2021 - 2030 (USD Million) 10.4.4.2.2. Mexico By Product Type, 2021 - 2030 (USD Million) 10.4.4.2.3. Mexico By Application, 2021 - 2030 (USD Million) 10.4.4.3. Rest of Latin America 10.4.4.3.1. Rest of the Latin America, By Sales Channel, 2021 - 2030 (USD Million) 10.4.4.3.2. Rest of the Latin America, By Product Type, 2021 - 2030 (USD Million) 10.4.4.3.3. Rest of the Latin America, By Application, 2021 - 2030 (USD Million) 10.5. MEA 10.5.1. MEA By Sales Channel, 2021 - 2030 (USD Million) 10.5.2. MEA By Product Type, 2021 - 2030 (USD Million) 10.5.3. MEA By Application, 2021 - 2030 (USD Million) 10.5.4. MEA By Region, 2021 - 2030 (USD Million) 11. Competitive Landscape 11.1 2MORROW, Inc. 11.1.1. Company overview 11.1.2. Financial performance 11.1.3. ProductPortfolio Analysis 11.1.4. Business Strategy & Recent Development 11.2. AKILI INTERACTIVE LABS, INC. 11.2.1. Company overview 11.2.2. Financial performance 11.2.3. Product Portfolio Analysis 11.2.4. Business Strategy & Recent Development 11.3. CLICK THERAPEUTICS, INC. 11.3.1. Company overview 11.3.2. Financial performance 11.3.3. Product Portfolio Analysis 11.3.4. Business Strategy & Recent Development 11.4. FITBIT, INC. (TWINE HEALTH, INC.) 11.4.1. Company overview 11.4.2. Financial performance 11.4.3. Product Portfolio Analysis 11.4.4. Business Strategy & Recent Development 11.5. HAPPIFY, INC. 11.5.1. Company overview 11.5.2. Financial performance 11.5.3. Product Portfolio Analysis 11.5.4. Business Strategy & Recent Development 11.6. Kaia Health 11.6.1. Company overview 11.6.2. Financial performance 11.6.3. Product Portfolio Analysis 11.6.4. Business Strategy & Recent Development 11.7. Livongo Health, Inc. 11.7.1. Company overview 11.7.2. Financial performance 11.7.3. Product Portfolio Analysis 11.7.4. Business Strategy & Recent Development 11.8. Medtronic Plc. 11.8.1. Company overview 11.8.2. Financial performance 11.8.3. Product Portfolio Analysis 11.8.4. Business Strategy & Recent Development 11.9. Omada Health, Inc. 11.9.1. Company overview 11.9.2. Financial performance 11.9.3. Product Portfolio Analysis 11.9.4. Business Strategy & Recent Development 11.10. Pear Therapeutics, Inc. 11.10.1. Company overview 11.10.2. Financial performance 11.10.3. Product Portfolio Analysis 11.10.4. Business Strategy & Recent Development 11.11. Proteus Digital Health, Inc. 11.11.1. Company overview 11.11.2. Financial performance 11.11.3. Product Portfolio Analysis 11.11.4. Business Strategy & Recent Development 11.12. Resmed, Inc. (Propeller Health). 11.12.1. Company overview 11.12.2. Financial performance 11.12.3. Product Portfolio Analysis 11.12.4. Business Strategy & Recent Development 11.13. Voluntis, Inc. 11.13.1. Company overview 11.13.2. Financial performance 11.13.3. Product Portfolio Analysis 11.13.4. Business Strategy & Recent Development 11.14. Welldoc, Inc. 11.14.1. Company overview 11.14.2. Financial performance 11.14.3. Product Portfolio Analysis 11.14.4. Business Strategy & Recent Development 11.15. F-star therapeutics 11.15.1. Company overview 11.15.2. Financial performance 11.15.3. Product Portfolio Analysis 11.15.4. Business Strategy & Recent Development 11.16. Omega therapeutics 11.16.1. Company overview 11.16.2. Financial performance 11.16.3. Product Portfolio Analysis 11.16.4. Business Strategy & Recent Development 11.17. G1 therapeutics 11.17.1. Company overview 11.18.2. Financial performance 11.17.3. Product Portfolio Analysis 11.17.4. Business Strategy & Recent Development 11.18. Gsk digital therapeutics 11.18.1. Company overview 11.18.2. Financial performance 11.18.3. Product Portfolio Analysis 11.18.4. Business Strategy & Recent Development 11.19. Q digital 11.19.1. Company overview 11.19.2. Financial performance 11.19.3. Product Portfolio Analysis 11.19.4. Business Strategy & Recent Development 11.20. Viridian therapeutics 11.20.1. Company overview 11.20.2. Financial performance 11.20.3. Product Portfolio Analysis 11.20.4. Business Strategy & Recent Development List of Tables (91 Tables) TABLE 1. Digital Therapeutics MARKET, By Sales Channel, 2021 - 2030 (USD Million) TABLE 2. Digital Therapeutics MARKET FOR B2C, BY REGION, 2021 - 2030 (USD Million) TABLE 3. Digital Therapeutics MARKET FOR Patients, BY REGION, 2021 - 2030 (USD Million) TABLE 4. Digital Therapeutics MARKET FOR Caregivers, BY REGION, 2021 - 2030 (USD Million) TABLE 5. Digital Therapeutics MARKET FOR B2B, BY REGION, 2021 - 2030 (USD Million) TABLE 6. Digital Therapeutics MARKET FOR Providers, BY REGION, 2021 - 2030 (USD Million) TABLE 7. Digital Therapeutics MARKET FOR Payers, BY REGION, 2021 - 2030 (USD Million) TABLE 8. Digital Therapeutics MARKET FOR Employers, BY REGION, 2021 - 2030 (USD Million) TABLE 9. Digital Therapeutics MARKET FOR Pharmaceutical Companies, BY REGION, 2021 - 2030 (USD Million) TABLE 10. Digital Therapeutics MARKET FOR Other Buyers, BY REGION, 2021 - 2030 (USD Million) TABLE 11. Digital Therapeutics MARKET, By Product Type, 2021 - 2030 (USD Million) TABLE 12. Digital Therapeutics MARKET FOR Software, BY REGION, 2021 - 2030 (USD Million) TABLE 13. Digital Therapeutics MARKET FOR Device, BY REGION, 2021 - 2030 (USD Million) TABLE 14. Digital Therapeutics MARKET, BY APPLICATION, 2021 - 2030 (USD Million) TABLE 15. Digital Therapeutics MARKET FOR Preventive Applications, BY REGION, 2021 - 2030 (USD Million) TABLE 16. Digital Therapeutics MARKET FOR Prediabetes, BY REGION, 2021 - 2030 (USD Million) TABLE 17. Digital Therapeutics MARKET FOR Obesity, BY REGION, 2021 - 2030 (USD Million) TABLE 18. Digital Therapeutics MARKET FOR Nutrition, BY REGION, 2021 - 2030 (USD Million) TABLE 19. Digital Therapeutics MARKET FOR Lifestyle Management, BY REGION, 2021 - 2030 (USD Million) TABLE 20. Digital Therapeutics MARKET FOR Other Preventive Applications, BY REGION, 2021 - 2030 (USD Million) TABLE 21. Digital Therapeutics MARKET FOR Treatment/Care-related Applications, BY REGION, 2021 - 2030 (USD Million) TABLE 22. Digital Therapeutics MARKET FOR Diabetes, BY REGION, 2021 - 2030 (USD Million) TABLE 23. Digital Therapeutics MARKET FOR CNS Disorders, BY REGION, 2021 - 2030 (USD Million) TABLE 24. Digital Therapeutics MARKET FOR Mental Health Disorder, BY REGION, 2021 - 2030 (USD Million) TABLE 25. Digital Therapeutics MARKET FOR Other CNS Digital therapeutics, BY REGION, 2021 - 2030 (USD Million) TABLE 26. Digital Therapeutics MARKET FOR Chronic Respiratory Disorders, BY REGION, 2021 - 2030 (USD Million) TABLE 27. Digital Therapeutics MARKET FOR Musculoskeletal Disorders, BY REGION, 2021 - 2030 (USD Million) TABLE 28. Digital Therapeutics MARKET FOR Cardiovascular Diseases, BY REGION, 2021 - 2030 (USD Million) TABLE 29. Digital Therapeutics MARKET FOR Smoking Cessation, BY REGION, 2021 - 2030 (USD Million) TABLE 30. Digital Therapeutics MARKET FOR Medication Adherence, BY REGION, 2021 - 2030 (USD Million) TABLE 31. Digital Therapeutics MARKET FOR Gastrointestinal Disorders, BY REGION, 2021 - 2030 (USD Million) TABLE 32. Digital Therapeutics MARKET FOR Substance Use & Addiction Management, BY REGION, 2021 - 2030 (USD Million) TABLE 33. Digital Therapeutics MARKET FOR Rehabilitation & Patient Care, BY REGION, 2021 - 2030 (USD Million) TABLE 34. Digital Therapeutics MARKET FOR Other Treatment/Care-related Applications, BY REGION, 2021 - 2030 (USD Million) TABLE 35. Digital Therapeutics MARKET, BY REGION, 2021 - 2030 (USD Million) TABLE 36. NORTH AMERICA Digital Therapeutics MARKET, BY COUNTRY, 2021 - 2030 (USD Million) TABLE 37. NORTH AMERICA Digital Therapeutics MARKET, By Sales Channel, 2021 - 2030 (USD Million) TABLE 38. NORTH AMERICA Digital Therapeutics MARKET, By Product Type, 2021 - 2030 (USD Million) TABLE 39. NORTH AMERICA Digital Therapeutics MARKET, BY APPLICATION, 2021 - 2030 (USD Million) TABLE 40. EUROPE Digital Therapeutics MARKET, BY COUNTRY, 2021 - 2030 (USD Million) TABLE 41. EUROPE Digital Therapeutics MARKET, By Sales Channel, 2021 - 2030 (USD Million) TABLE 42. EUROPE Digital Therapeutics MARKET, By Product Type, 2021 - 2030 (USD Million) TABLE 43. EUROPE Digital Therapeutics MARKET, BY APPLICATION, 2021 - 2030 (USD Million) TABLE 44. ASIA-PACIFIC Digital Therapeutics MARKET, BY COUNTRY, 2021 - 2030 (USD Million) TABLE 45. ASIA-PACIFIC Digital Therapeutics MARKET, By Sales Channel, 2021 - 2030 (USD Million) TABLE 46. ASIA-PACIFIC Digital Therapeutics MARKET, By Product Type, 2021 - 2030 (USD Million) TABLE 47. ASIA-PACIFIC Digital Therapeutics MARKET, BY APPLICATION, 2021 - 2030 (USD Million) TABLE 48. LAMEA Digital Therapeutics MARKET, BY COUNTRY, 2021 - 2030 (USD Million) TABLE 49. LAMEA Digital Therapeutics MARKET, By Sales Channel, 2021 - 2030 (USD Million) TABLE 50. LAMEA Digital Therapeutics MARKET, By Product Type, 2021 - 2030 (USD Million) TABLE 51. LAMEA Digital Therapeutics MARKET, BY APPLICATION, 2021 - 2030 (USD Million) TABLE 52. 2MORROW, Inc.: COMPANY SNAPSHOT TABLE 53. 2MORROW, Inc.: OPERATING SEGMENTS TABLE 54. AKILI INTERACTIVE LABS, INC.: COMPANY SNAPSHOT TABLE 55. AKILI INTERACTIVE LABS, INC.: OPERATING SEGMENTS TABLE 56. CLICK THERAPEUTICS, INC.: COMPANY SNAPSHOT TABLE 57. CLICK THERAPEUTICS, INC.: OPERATING SEGMENTS TABLE 58. FITBIT, INC. (TWINE HEALTH, INC.) : COMPANY SNAPSHOT TABLE 59. FITBIT, INC. (TWINE HEALTH, INC.) : OPERATING SEGMENTS TABLE 60. HAPPIFY, INC.: COMPANY SNAPSHOT TABLE 61. HAPPIFY, INC.: OPERATING SEGMENTS TABLE 62. Kaia Health : COMPANY SNAPSHOT TABLE 63. Kaia Health : OPERATING SEGMENTS TABLE 64. Livongo Health, Inc.: COMPANY SNAPSHOT TABLE 65. Livongo Health, Inc.: OPERATING SEGMENTS TABLE 66. Medtronic Plc.: COMPANY SNAPSHOT TABLE 67. Medtronic Plc.: OPERATING SEGMENTS TABLE 68. Omada Health, Inc.: COMPANY SNAPSHOT TABLE 69. Omada Health, Inc.: OPERATING SEGMENTS TABLE 70. Pear Therapeutics, Inc.: COMPANY SNAPSHOT TABLE 71. Pear Therapeutics, Inc.: OPERATING SEGMENTS TABLE 72. Proteus Digital Health, Inc.: COMPANY SNAPSHOT TABLE 73. Proteus Digital Health, Inc.: OPERATING SEGMENTS TABLE 74. Resmed, Inc. (Propeller Health): COMPANY SNAPSHOT TABLE 75. Resmed, Inc. (Propeller Health): OPERATING SEGMENTS TABLE 76. Voluntis, Inc.: COMPANY SNAPSHOT TABLE 77. Voluntis, Inc.: OPERATING SEGMENTS TABLE 78. Welldoc, Inc.: COMPANY SNAPSHOT TABLE 79. Welldoc, Inc.: OPERATING SEGMENTS TABLE 80. F-star therapeutics: COMPANY SNAPSHOT TABLE 81. F-star therapeutics: OPERATING SEGMENTS TABLE 82. Omega therapeutics: COMPANY SNAPSHOT TABLE 83. Omega therapeutics: OPERATING SEGMENTS TABLE 84. G1 therapeutics: COMPANY SNAPSHOT TABLE 85. G1 therapeutics: OPERATING SEGMENTS TABLE 86. Gsk digital therapeutics: COMPANY SNAPSHOT TABLE 87. Gsk digital therapeutics: OPERATING SEGMENTS TABLE 88. Q digital: COMPANY SNAPSHOT TABLE 89. Q digital: OPERATING SEGMENTS TABLE 90. Viridian therapeutics: COMPANY SNAPSHOT TABLE 91. Viridian therapeutics: OPERATING SEGMENTS List of Figures (22 Figures) Figure 1 Digital Therapeutics Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Digital Therapeutics Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Digital Therapeutics Market: Product-Based Estimation Figure 6 Top 20 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Digital Therapeutics, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Digital Therapeutics, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 By Product Type, 2019 vs. 2025 (USD Million) Figure 12 Share, By Application, 2019 vs. 2025 (USD Million) Figure 13 Share, By Sales Channel, 2019 vs. 2025 (USD Million) Figure 14 Geographical Snapshot of the Figure 15 B2B to Witness Higher CAGR in for Sales Channel Segment during Forecast Period. Figure 16 Treatment/Care-related Applications to Witness Higher CAGR in for Application Segment during Forecast Period. Figure 17 Software to Witness Higher CAGR in for Product Type Segment during Forecast Period. Figure 18 North America region Accounted for the Largest Share of the , By Regional Basis, in 2019 Figure 19 Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Snapshot Figure 21 Asia Pacific: Snapshot Figure 22 Vendor Dive: Evaluation Overview